Trial Search Results

The clonoSEQ® Watch Registry

This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Adaptive Biotechnologies

Stanford Investigator(s):


  • Diagnostic Test: clonoSEQ Assay


Inclusion Criteria:

   1. Patients must be able to provide written informed consent

   2. A decision has been made by the treating provider to use the clonoSEQ Assay as part of
   routine clinical care

   3. Age ≥ 18 years;

   4. Documented hematologic malignancy (any of the below):

      1. MM

      2. ALL (B and T-cell subtypes)

      3. B-cell NHL (all sub types)

      4. CLL

      5. Other lymphoid malignancies (upon review and approval by study chair)

Exclusion Criteria:

Patients must not meet any of the following criteria in order to be enrolled into the

   1. Concurrent enrollment in a clinical trial where treatment decisions and patterns are
   dictated per protocol

   2. A decision has been made by the treating provider to not use the clonoSEQ Assay as
   part of routine clinical care

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Janet McDowell